All In Biotech

Drug Trial Radar · NCT02968927

TB Host Directed Therapy

A Ph2 Randomized Trial to Evaluate the Safety Preliminary Efficacy and Biomarker Response of Host Directed Therapies Added to Rifabutin-modified Standard Therapy in Adults With Drug-Sensitive Smear-Positive Pulmonary TB

Last checked: Nov 20, 2026Latest source record: Jan 10, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

200

Actual

Start

Nov 2016

Primary completion

Sep 2018

Study completion Dec 2020

Sponsor

Lead sponsor
The Aurum Institute NPCAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 21, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To examine the safety and preliminary efficacy of multiple adjunctive host directed TB therapies (TB HDT), to assess their potential to shorten TB treatment and/or prevent permanent lung damage.

Conditions

  • Tuberculosis

Interventions

  • Everolimus 0.5 MGDrug

  • Auranofin 6 MGDrug

  • Vitamin D3Drug

  • CC-11050Drug

  • 2HRbZE/4HRbDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SAEs and SUSARsTime frame: through day 180

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Aurum Institute: Tembisa Clinical Research Centre

    Tembisa, Gauteng, South Africa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.